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(Author list continued on next page)SummaryGenome-wide association studies (GWASs) have identified thousands of cancer risk loci revealing many risk regions shared across mul-
tiple cancers. Characterizing the cross-cancer shared genetic basis can increase our understanding of global mechanisms of cancer devel-
opment. In this study, we collected GWAS summary statistics based on up to 375,468 cancer cases and 530,521 controls for fourteen
types of cancer, including breast (overall, estrogen receptor [ER]-positive, and ER-negative), colorectal, endometrial, esophageal, glioma,
head/neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancer, to characterize the shared genetic basis of cancer risk. We
identified thirteen pairs of cancers with statistically significant local genetic correlations across eight distinct genomic regions. Specif-
ically, the 5p15.33 region, harboring the TERT and CLPTM1L genes, showed statistically significant local genetic correlations for mul-
tiple cancer pairs. We conducted a cross-cancer fine-mapping of the 5p15.33 region based on eight cancers that showed genome-wide
significant associations in this region (ER-negative breast, colorectal, glioma, lung, melanoma, ovarian, pancreatic, and prostate cancer).
We used an iterative analysis pipeline implementing a subset-based meta-analysis approach based on cancer-specific conditional ana-
lyses and identified ten independent cross-cancer associations within this region. For each signal, we conducted cross-cancer fine-map-
ping to prioritize the most plausible causal variants. Our findings provide a more in-depth understanding of the shared inherited basis
across human cancers and expand our knowledge of the 5p15.33 region in carcinogenesis.Introduction
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Genome-wide association studies (GWASs) of specific
types of cancer have identified genetic loci significantly
associated with susceptibility to malignancies. In a recent
study of 18 types of cancer in European ancestry popula-
tions,5 the authors identified 17 genome-wide significant
variants that were associated with the risk of at least two
cancers with the same direction of effect. The 8q24 region
has been long recognized as a pleiotropic locus, where ge-
netic variants have been associated with the risk of breast,
colorectal, endometrial, glioma, ovarian, pancreatic, and
prostate cancer, among others.6–16 The 5p15.33 region
has been associated with more than ten types of cancer,
with multiple independent risk alleles identified.17–24
Various biological mechanisms, including inflammation,
epigenetics, gene expression, and telomere structure,
have been proposed to explain these identified pleiotropic
associations. For example, the 5p15.33 region harbors the
TERT gene, which encodes the catalytic subunit of telome-
rase,25 as well as the CLPTM1L gene, which encodes the
cleft lip and palate-associated transmembrane-1 like pro-
tein.26
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approach implemented in the GCTA tool,27 one study
quantified the pairwise genetic correlation among 13 types
of cancers in European ancestry populations.28 Four pairs
of cancers, including bladder-lung, testis-renal, lym-
phoma-osteosarcoma, and lymphoma-leukemia, demon-
strated statistically significant shared heritability. We
have previously applied linkage disequilibrium (LD) score
regression29,30 on cancer GWAS summary statistics and
observed significant genetic correlations between multiple
solid tumor pairs, including colorectal-lung, colorectal-
pancreatic, breast-colorectal, breast-lung, breast-ovarian,
and lung-head/neck cancer.31,32 However, these studies
only quantified the pairwise genetic correlation on a
genome-wide scale, ignoring variations in the local genetic
correlation across the genome. As shared heritability be-
tween cancers may not be uniformly distributed across
the genome, such limitation may lead to missed opportu-
nities to discover specific regions with crucial contribution
to the oncogenesis of multiple cancers.33
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LD pattern in the 1000 Genomes (1000G) Europeaneå, Sweden; 27Department of Environmental Medicine and Public Health,
Agency for Research on Cancer, World Health Organization, Lyon, France;
ntre, University Hospitals Bristol andWeston NHS Foundation Trust and the
, Bristol, UK; 31Department of Human Genetics, Graduate School of Public
Center, Pittsburgh, PA, USA; 33Department of Epidemiology, Gillings School
ill, NC, USA; 34UNC Lineberger Comprehensive Cancer Center, Chapel Hill,
Medicine, Houston, TX, USA; 36Department of Environmental Health, Har-
logy and Functional Genomics of Multifactorial Diseases Team, Institut Na-
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Table 1. Overview of the cancer GWAS datasets included in this study
Cancer types No. of cases No. of controls No. of SNPs after QCa Reference
Breast, overall 122,977 105,974 9,934,907 Michailidou et al., 201738
Breast, ER-negative 21,468 100,564 9,942,394 Michailidou et al., 201738
Breast, ER-positive 69,501 95,042 10,267,258 Michailidou et al., 201738
Colorectal 55,168 65,160 7,910,462 Huyghe et al., 201939
Endometrial 12,906 108,979 11,595,492 O’Mara et al., 201816
Esophageal 4,112 13,663 9,038,176 Gharahkhani et al., 201640
Glioma 12,488 18,169 6,931,587 Melin et al., 201741
Head/neck 6,034 6,585 7,471,918 Lesseur et al., 201642
Lung 29,266 56,450 7,673,197 McKay et al., 201743
Melanoma 12,814 23,203 7,748,523 Law et al., 201544
Ovarian 22,406 40,951 9,870,154 Phelan et al., 201745
Pancreatic 8,638 12,217 9,568,913 Klein et al.,201846
Prostate 79,166 61,106 10,002,813 Schumacher et al., 201847
Renal 10,784 20,407 8,362,393 Scelo et al., 201748
aFiltered out variants with imputation quality score < 0.3, minor allele frequency (MAF) < 1%, and |log odds ratio| > 3.ancestry populations,34 we systematically estimated pair-
wise local genetic correlations between cancers. After ad-
justing for multiple comparisons, we identified thirteen
pairs of cancers with statistically significant local genetic
correlations across eight distinct genomic regions. Among
these, a 1.2 Mb region at 5p15.33, harboring the TERT and
CLPTM1L genes, showed significant local genetic correla-
tions across six pairs of cancers, including breast (overall
and estrogen receptor [ER]-negative), colorectal, glioma,
lung, melanoma, pancreatic, and prostate cancer. We
then utilized an iterative analysis pipeline implementing
a subset-based meta-analysis approach (Association Anal-
ysis for SubSETs [ASSET])35 and a conditional analysis
tool (COndition and JOint analysis tool implemented in
the Genome-wide Complex Trait Analysis software,
COJO-GCTA)36 and identified ten independent cross-can-
cer signals within the 1.2 Mb region. For each independent
signal, we conducted multi-cancer fine-mapping analysis
using PAINTOR37 to prioritize the variants with the highest
posterior probability of being causal. Our study provides
novel evidence of shared genetic susceptibility across
cancer types and contributes crucial information toward
understanding the common genetic mechanisms of
carcinogenesis.Material and methods
Study sample and genotype quality control
We collected the meta-analysis results from a total of 14 cancer
GWASs: breast (overall, ER-positive, and ER-negative),38 colo-
rectal,39 endometrial,16 esophageal,40 glioma,41 head/neck,42
lung,43 melanoma,44 ovarian,45 pancreatic,46 prostate,47 and renal
cancer.48 Sample size for each cancer is listed in Table 1. The GWAS
summary statistics for each cancer were provided by the corre-H
sponding collaborative consortia. Details on study characteristics
and subjects contributing to each cancer-specific GWAS summary
dataset have been described in the original cancer-specific publica-
tions. All the GWAS results used in this study were based on Euro-
pean ancestry populations. Genomic positions were based on
Genome Reference Consortium GRCh37 (hg19).
Individual cancer GWASs were primarily imputed to the 1000G
reference panels.49 Breast, ovarian, pancreatic, and prostate cancer
used the 1000G phase 3 v.5 reference panel; colorectal cancer used
the Haplotype Reference Consortium (HRC); head/neck cancer
usedHRC; renal cancer used 1000Gphase 1 v.3;metanalysis results
formelanomaGWASswere based on studiesmajorly imputedwith
1000G phase 1 v.3;44 lung cancer used amix between 1000G phase
1 and hase 3; glioma used a mix between 1000G phase 3, UK10K,
andHRC; esophageal cancer used 1000G phase 1; and endometrial
cancer used amix between 1000Gphase 3 v.5 andUK10K. For each
dataset, we conducted comprehensive quality control to clean and
harmonize the GWAS summary statistics across cancers. This
included: (1) removing duplicate, structural, multi-allelic, and
ambiguous variants; (2) confirming that strand and alleles at each
variant were consistent across cancers; (3) creating a common
unique marker ID; and (4) removing analytic artifacts (e.g., com-
mon variants with reported |log odds ratio| > 3). We also removed
anyvariantswith imputationquality score<0.3 orminor allele fre-
quency (MAF) < 0.01. After manual inspection of the results, we
conducted additional ad hoc cleaning for individual cancer results
to remove any obvious technical artifacts.Genetic correlations due to sample overlap
We estimated the number of controls overlapping between pairs of
cancers, as these would induce a correlation in the GWAS sum-
mary statistics between cancers. We identified participating
studies and any publicly available datasets (e.g., Wellcome Trust
Case Control Consortium) to calculate the maximum number of
controls overlapping between any two cancers. We also employed
the tetrachoric correlation between binary-transformed GWASuman Genetics and Genomics Advances 2, 100041, July 8, 2021 3
Figure 1. Analytical pipeline for the study
Regions with significant pairwise local genetic correlation were
first identified by rHESS. For regions harboring disproportionally
high shared heritability across cancers, joint test of ASSET two-
sided meta-analysis and COJO conditional analysis was then
repeatedly conducted to identify independent signals, until no
variant reached genome-wide significance (p < 5 3 108) in two-
sided ASSETmeta-analysis. For each signal, GWAS summary statis-
tics conditional on other signals of selected cancer were used in
multi-trait fine-mapping to estimate the posterior probability of
being causal.summary Z scores to determine putative sample overlap.50,51 To
avoid induced correlations due to a shared polygenic architecture,
we removed all cancer-specific variants with association p < 0.1.
We observed six pairs of cancers that had correlations > 0.05,
and these all reflected previously known documented relation-
ships where controls were shared between groups (Table S1). Pairs
with correlations > 0.05 included breast and endometrial (0.08),
ER-positive breast and endometrial (0.06), breast and ovarian
(0.05), esophageal and melanoma (0.08), lung and head/neck
(0.07), and lung and renal cancer (0.07).
Local genetic correlation estimation
To identify regions in the genome with local genetic correlations
between pairs of cancers, we used rHESS52 (Heritability Estimation
using Summary Statistics), which first estimates the local SNP-her-
itability for each cancer within each region based on summary sta-
tistics53 and then quantifies the covariance and correlation be-
tween pairs of cancers. Based on the LD pattern in 1000G
European ancestry populations,34 rHESS partitions the genome
into 1,703 approximatively independent LD blocks. We took sam-
ple overlap between pairs of cancers into account as described
above. Pairwise local genetic correlations were considered statisti-
cally significant if the p value < 0.05/1,703 ¼ 2.94 3 105.
Searching for independent signals shared across cancers
Basedon the local genetic correlation results,we identified a 1.2Mb
region at 5p15.33 (hg19 coordinates: 82,252–2,132,442 bp)4 Human Genetics and Genomics Advances 2, 100041, July 8, 2021harboring significant local heritability for multiple cancer pairs
(see Results).We selected eight types of cancers (ER-negative breast,
colorectal, glioma, lung, melanoma, ovarian, pancreatic, prostate)
that had genome-wide significant associations in the region and
showed evidence of pairwise genetic correlation (p < 0.05) with
at least one other cancer having genome-wide significant associa-
tions in this region, which includes the TERTandCLPTM1L genes.
We first performed a conditional analysis using COJO-GCTA36 on
each individual cancer adjusting for the variant with the smallest
p value, until no variant had a conditional p < 5 3 108. We then
performed pairwise colocalization analyses using COLOC54 to
assess if any cancers shared causal variants, after controlling for
the independent signals identified inanalysis of individual cancers.
To comprehensively enumerate the independent cross-cancer sig-
nals within this locus, we then used an agnostic subset-based
meta-analysis (ASSET)35 to identify variants with the strongest
cross-cancer associations in this region (Figure 1). ASSET allows
for opposite direction of effects across traits when assessing the as-
sociation between variants and multiple traits, as implemented in
the ‘‘two-sided’’ option in ASSET. Overlap in controls between
GWASs was addressed by using the tetrachoric correlation, as
described above. To determine the number of independent signals
withina region,we reranall individual cancerGWASs conditioning
on the top variant identified byASSETusingCOJO-GCTA. The con-
ditional analysismaybe subject to themismatchof LDbetween the
reference panel and the population that generated the GWAS re-
sults. Consequently, we created a LD reference panel for all can-
cer-specific conditional analyses using European ancestry breast
cancer controls (n ¼ 40,401),38 which was the largest population
with genotype data available. After generating updated cancer-spe-
cific GWAS summary statistics conditioned on themost significant
variant (topvariant),we reran the two-sidedASSETmeta-analysis to
identify any additional significant cross-cancer signals. We then
added the new top variant from the ASSET analysis to the list of
lead SNPs and reran all cancer GWASs conditioning on all lead var-
iants usingCOJO-GCTA.We iteratively ran cancer-specific analyses
conditioning on the identified top variants using COJO-GCTA and
ran two-sided ASSETon the resulting cancer-specific association re-
sults.We repeated this procedure until no variant reached genome-
wide significance in the two-sided ASSET meta-analysis. The lead
variants that resulted from the two-sided ASSET meta-analyses
based on the conditional cancer-specific results were regarded as
candidate variants that independently affect the risk of multiple
cancers. Using this approach, we identified a total of ten indepen-
dent signals within the 5p15.33 region.
Multi-trait fine-mapping
For each of the ten cross-cancer signals in the 5p15.33 region iden-
tified by our ASSET-COJO analysis, we created new cancer-specific
GWAS summary statistics adjusting for the other nine top variants
and estimated variant-specific posterior probabilities of causality
using PAINTOR v.3.0.37 We varied the set of cancers included in
the fine-mapping analyses of each of the ten independent cross-
cancer signals as we hypothesized that not all cancers would share
the same causal variant for each independent signal, but, rather,
different combinations of cancers contributed to each of the ten in-
dependent signals. This was also supported by the ASSET analyses,
where not all cancers contributed to the top signal for each of the
ten conditional meta-analyses. In particular, ASSET provides the
subset of traits that contribute to the smallest variant-specific
meta-analysis p value. For each variant, two subsets are reported,
with the first including traits with a positive association and the
Table 2. Genomic regions with statistically significant local genetic correlations between cancers
Cancer site 1 Cancer site 2 Region Region start Region end No. of SNPs Direction p valuea
ER-negative breast prostate 1q32 203334734 204681068 2,364 negative 3.45E06
Colorectal prostate 4q24 105305294 107501305 2,986 positive 1.05E05
Glioma prostate 5p15.33 982252 2132442 2,631 negative 4.03E19
Colorectal glioma 5p15.33 982252 2132442 2,465 negative 1.24E05
ER-negative breast prostate 5p15.33 982252 2132442 3,111 negative 1.90E05
ER-negative breast glioma 5p15.33 982252 2132442 2,631 positive 2.40E05
Melanoma pancreatic 5p15.33 982252 2132442 2,849 positive 4.85E06
Lung pancreatic 5p15.33 982252 2132442 2,935 negative 1.39E07
Overall breast colorectal 5q11.2 55417349 56621102 2,131 positive 1.97E05
Colorectal prostate 8q24 126410917 128659111 4,275 positive 1.97E16
ER-positive breast prostate 10q26.13 123231465 123900545 1,481 negative 1.22E06
Endometrial prostate 17q12 34469036 36809344 2,748 positive 5.01E09
ER-negative breast ovarian 19p13.11 16374416 18409862 4,103 positive 1.11E07
Local genetic correlation between cancers across the genome (N ¼ 1,703 regions) was estimated using HESS.
aCutoff of the statistical significance was defined as p < 0.05/1,703 ¼ 2.94E05, after adjusting for multiple comparison.second including traits with a negative association. For each of the
ten independent signals, we included a specific cancer in the PAIN-
TOR fine-mapping analysis if: (1) it was one of the cancers selected
by ASSET as a contributing phenotype in the corresponding two-
sided ASSET analysis of the lead variant, or (2) the lead variant
showed genome-wide significant association for that cancer in
theunadjusted cancer-specificGWAS. For each independent signal,
only SNPs with data for all relevant cancers were included. We ran
PAINTOR under the assumption that there was only one causal
variant underlying that signal. We used the same LD reference
panel for the fine-mapping analysis as we did for the conditional
analysis. In our primary analyses, we performed the fine-mapping
with no functional annotation implemented. Since regulation of
TERTandCLPTM1L expressionhas been linked to open chromatin
conformation in previous analyses,55,56 we conducted a secondary
analysis incorporating tissue-specific open chromatin annotations
as functional prior. We obtained open chromatin narrow peaks
identified fromnormal tissueorprimary cell linesof the relevantor-
gans of each signal, based on the ENCODE project.57 By overlap-
ping variants with open chromatin peaks, we generated a binary
matrix for the region, which was then implemented as the func-
tional prior in the fine-mapping analysis.Results
Local genetic correlation revealed specific regions in the
genome with shared heritability across cancers
We first partitioned the genome into 1,703 regions and
estimated the pairwise local genetic correlation between
fourteen types of cancers. After adjusting for multiple
comparisons (p value < 0.05/1,703 ¼ 2.94 3 105), we
identified thirteen pairs of cancers with statistically signif-
icant local genetic correlation across eight distinct
genomic regions (Table 2). Among these, seven cancer
pairs had positive genetic correlation (4q24: colorectalH
and prostate; 5p15.33: ER-negative breast and glioma,
melanoma and pancreatic; 5q11.2: overall breast and colo-
rectal; 8q24: colorectal and prostate; 17q12: endometrial
and prostate; 19p13.11: ER-negative breast and ovarian),
while six others showed negative genetic correlations
(1q32: ER-negative breast and prostate; 5p15.33: glioma
and prostate, colorectal and glioma, ER-negative breast
and prostate, lung and pancreatic; 10q26.13: ER-positive
breast and prostate). The local genetic correlation results
mirrored previous observations, in that genome-wide sig-
nificant variants for the identified regions have been pre-
viously reported for the individual cancers. For example,
colorectal and prostate cancer showed significant local
genetic correlation on chromosome 8 (126,410,917–
128,659,111 bp), overlapping the 8q24.21 region, which
harbors susceptibility variants for more than ten types
of cancers. Similarly, a region on chromosome 19
(16,374,416–18,409,862 bp) showed significant local ge-
netic correlation between ovarian and ER-negative breast
cancer, both of which have genome-wide significant sus-
ceptibility variants in this region. One region on chromo-
some 5 (982,252–2,132,442 bp), harboring the TERT and
CLPTM1L genes, showed significant local genetic correla-
tion across six pairs of cancers, including ER-negative
breast, colorectal, glioma, lung, melanoma, pancreatic,
and prostate cancer (Figure 2). Interestingly, the direction
of the genetic correlations varied between cancer pairs. For
example, glioma showed significant but opposite local ge-
netic correlations with ER-negative breast (rg ¼ 0.0014,
p ¼ 2.40 3 105) and colorectal cancer (rg ¼ 0.0015,
p ¼ 1.24 3 105). Similarly, pancreatic cancer had a posi-
tive local genetic correlation with melanoma (rg ¼ 0.0034,
p ¼ 4.85 3 106) but a negative genetic correlation with
lung cancer (rg ¼ 0.0025, p ¼ 1.39 3 1057).uman Genetics and Genomics Advances 2, 100041, July 8, 2021 5
Figure 2. Pairwise local genetic correlation between selected cancer types at chromosome 5p15.33 (982,252–2,132,442 bp)
Cancer pairs with statistically significant (p value < 0.05/1,703 ¼ 2.94 3 105) local genetic correlation are annotated with an asterisk.Distinct patterns of regional GWAS association p values
for the variants at 5p15.33
Based on the local genetic correlation results, the 5p15.33
region may harbor key genetic variants related to multiple
cancer types. Indeed, multiple susceptibility variants in
this region have been reported for at least ten cancer types,
including ER-negative breast, colorectal, glioma, lung, mel-
anoma, ovarian, pancreatic, and prostate cancer. To obtain
a more complete understanding of the association patterns
in this region, we created cancer-specific regional associa-
tion plots for 5p15.33 (Figure 3A). We observed three
different patterns of association. Pattern A, which includes
breast (overall, ER-positive, and ER-negative), colorectal,
glioma, ovarian, and prostate cancer, displayed one
sharp genome-wide significant signal in a narrow region
(~30 kb) overlapping the TERT gene (chr5: 1,253,282–
1,295,178 bp). Pattern B, which includes lung, melanoma,
and pancreatic cancer, has a broader genome-wide signifi-
cant signal overlapping both the TERT (chr5: 1,253,282–
1,295,178 bp) and CLPTM1L genes (chr5: 1,317,869–
1,345,180 bp) (Figure 3B). Pattern C, which includes endo-
metrial, esophageal, head/neck, and renal cancer, did not
have a genome-wide significant signal in this region
(Figure 3C). Interestingly, the distribution of variant-spe-
cific associations for some cancers was highly similar but
in the opposite direction (Figure 3D), suggesting that
GWAS associations discovered in this region may underly
tissue-specific regulations across cancers. The association-
based classification of cancers was highly consistent with
our local genetic correlation results. All cancer types
showing shared significant local genetic correlation in6 Human Genetics and Genomics Advances 2, 100041, July 8, 2021this region were in either pattern A or B, and thus we
excluded the cancers belonging to pattern C for further an-
alyses. For breast cancer, we limited our analysis to ER-
negative breast cancer, as it had the strongest association
at 5p15.33. Along with colorectal, glioma, lung, mela-
noma, ovarian, pancreatic, and prostate cancer, a total
number of eight cancer types were used in the fine-map-
ping cross-cancer analyses.
Ten independent signals were identified based onmulti-
cancer meta-analysis results
Given the important biological function of the TERT and
CLPTM1L genes, previous cancer fine-mapping efforts in
this region, and the appearance of multiple association
peaks for some of the cancers, it is plausible to assume
that multiple variants in this region affect cancer risk inde-
pendently. To test this assumption, we performed a condi-
tional analysis using COJO-GCTA for each cancer to
enumerate the independent signals at the 5p15.33 region.
Six of the eight cancers of interest, including ER-negative
breast, colorectal, glioma, lung, pancreatic, and prostate,
were identified with two or more independent variants
(Table S2). A total number of thirteen variants were iden-
tified, of which four were shared by two cancer types. By
using conditional analysis results of each cancer, we
then assessed the probability of two cancers sharing a sin-
gle causal variant using a Bayesian-based colocalization
approach.54 Glioma and melanoma were estimated to
be likely sharing a causal variant (posterior probability
[PP] ¼ 0.519; Table S3), even after controlling for the effect
of identified signals of individual cancers. These results
Figure 3. Categorizing 14 cancer types into three tiers based on their p value distribution at 5p15.33
Pattern A cancers (A) have one single peak by the TERT gene; pattern B cancers (B) have a broader signal at the CLPTM1L gene as well as a
signal by the TERT gene; pattern C cancers (C) have no genome-wide significant association in this region. Genome-wide significant
levels at p value ¼ 5 3 108 are marked with red dashed line in (A)–(C). Distribution of Z scores at the 5p15.33 region from the
GWAS results of ER-negative breast, glioma, and prostate cancer (D). Only variants with p < 0.05 for both cancers are included. While
the associations for ER-negative breast cancer and glioma overlap, the SNP associations with ER-negative breast cancer and prostate, as
well as glioma and prostate, are in opposite directions.
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Figure 4. Distribution of two-sided subset-based meta-analysis p values across eight cancer types at the 5p15.33 region
Index variants of ten independent candidate signals, identified by the iterative COJO-ASSET analysis, are annotated and marked in red.suggest that multiple independent cross-cancer signals
may exist in this region.
However, current state-of-the-art statistical fine-map-
ping tools often struggle to make inference of causality un-
der the assumption of multiple causal variants. Further, it
is likely that not all cancers share all causal variants. To
get an estimate of the number of independent association
signals across cancers in this region, we conducted iterative
meta-analyses using individual cancer-specific association
results from conditional analysis as generated by COJO-
GCTA (see Material and methods). We adopted the two-
sided analysis scheme in ASSET to allow for the detection
of effects in opposite directions.
The strongest associated variant in the two-sided ASSET
meta-analysis was rs10069690 (chr5: 1,279,790, p ¼
4.05 3 10126; Figure 4), which was positively associated
with ER-negative breast cancer and gliomawhile negatively
associatedwith pancreatic andprostate cancer.We adjusted
the cancer-specific GWAS results for rs10069690 using
COJO-GCTA, and then reran the two-sided ASSET meta-
analysis with the rs10069690-adjusted cancer-specific re-
sults. We observed the strongest association for rs465498
(chr5: 1,325,803, p ¼ 1.75 3 1059), which was positively
associatedwithmelanoma and pancreatic cancer and nega-
tively associated with lung cancer. We added rs465498 to
the set of variants to be conditioned on in the cancer-spe-
cific GWASs and iterated this process until no variant
reached genome-wide significance (p < 5 3 108) in two-
sided ASSET meta-analysis. In the end, we obtained ten8 Human Genetics and Genomics Advances 2, 100041, July 8, 2021conditionally independent significant SNPs (Table 3;
Figure S1). The pairwise r2 between the ten SNPs ranged be-
tween 0.001 and 0.294 as based on 1000G European
ancestry data,58 which indicated that the pairwise correla-
tions between the identified signals were weak (Figure 5).
For each of the ten independent signals, the number of
cancer types contributing to the association as identified
by ASSET ranged from two to eight. Although SNPs
rs10069690 and rs7705526 were both genome-wide signif-
icant variants for ovarian cancer (p ¼ 1.74 3 108 and
1.34 3 109, respectively), ASSET did not include ovarian
cancer as a contributing cancer to the meta-analysis results
for either of the SNPs. To ensure that we included all rele-
vant cancers in the fine-mapping analysis of each indepen-
dent signal, we extracted the original cancer GWAS results
for the ten independent SNPs and manually added any
cancers to the list of contributing cancers if that cancer
showed a genome-wide significant association with a spe-
cific SNP but was not included on the list of traits opti-
mizing the ASSET meta-analysis. For each of the ten
SNPs, we then applied COJO-GCTA on each included can-
cer GWAS dataset to obtain cancer-specific results condi-
tioned on the other nine lead SNPs and used these adjusted
summary statistics in the fine-mapping analyses.
Cross-cancer fine-mapping proposes candidate causal
variants shared by cancers
To identify candidate causal SNPs within the ten indepen-
dent signals identified in the conditional analyses, we
Table 3. Ten independent cross-cancer signals in 5p15.33 region identified in the joint analysis of COJO-ASSET




ER-neg BrCa Colorectal Glioma Lung Melanoma Ovarian Pancreatic Prostate
Initiation rs10069690 (5:1279790:C:T) 4.05E126 set 1: ER-neg BrCa, glioma;
set 2: pancreatic, prostate
1.34E35* 1.13E01 2.32E66* 9.39E01 9.08E01 1.74E08* 3.29E03 1.44E45*
1 rs465498 (5:1325803:A:G) 1.75E59 set 1: melanoma, pancreatic;
set 2: lung
1.61E02 3.89E02 6.85E05 2.68E32* 2.08E17* 1.49E01 7.45E17* 9.15E05
2 rs2853677 (5:1287194:G:A) 3.24E39 set 1: ER-neg BrCa, colorectal,
lung; set 2: glioma, melanoma,
ovarian, pancreatic, prostate
4.94E05 3.65E10* 1.08E28* 2.66E18* 1.12E02 1.49E06 2.87E08* 1.53E02
3 rs11414507 (5:1291331:A:AC) 1.29E19 set 1: ER-neg BrCa; set 2:
prostate
1.34E16* NA NA NA NA 1.63E04 8.18E01 1.61E45*
4 rs35033501 (5:1253918:C:T) 9.18E15 set 1: lung, melanoma, prostate;
set 2: ER-neg BrCa, pancreatic
9.90E05 8.55E03 1.24E02 3.84E01 3.66E02 5.55E01 4.48E05 2.37E15*
5 rs7705526 (5:1285974:C:A) 1.42E11 set 1: glioma, lung, melanoma;
set 2: ER-neg BrCa, colorectal,
pancreatic, prostate
1.37E04 3.17E04 5.01E61* 1.01E18* 3.24E03 1.34E09* 2.15E03 2.78E14*
6 rs192723047 (5:1273183:A:G) 1.63E11 set 1: prostate; set 2: ER-neg BrCa 4.37E17* NA NA NA NA 1.21E02 8.96E02 5.40E24*
7 rs35226131 (5:1295373:C:T) 2.32E09 set 1: pancreatic; set2:
colorectal, glioma, prostate
8.83E02 5.17E07 8.66E01 NA NA 3.63E01 4.30E08* 3.20E06
8 rs35334674 (5:1292299:G:A) 1.24E08 set 1: ER-neg BrCa, pancreatic;
set 2: colorectal, glioma, lung,
prostate
3.36E02 4.40E07 4.07E02 2.15E02 NA 5.93E01 1.43E02 3.23E02
9 rs3888705 (5:1298645:G:A) 2.65E08 set 1: ER-neg BrCa, colorectal,
ovarian; set 2: pancreatic, prostate
1.78E02 1.04E03 9.32E07 3.62E03 NA 2.75E03 7.13E01 1.94E03
10 rs148487301 (5:1318797:T:C) 8.70E06 not reached genome-wide
significance, iteration stopped
*Genome-wide significance with p value < 5 3 108. BrCa, breast cancer; NA, the SNP was not included in the GWAS results of corresponding cancer..
ap values from the ASSET meta-analysis allowing opposite direction of the effect (two-sided analysis).
bCancer subsets included in the two-sided ASSET meta-analysis with best p value. Set 1/2 represents the selected cancer types with positive/negative association with the SNP.











































Figure 5. Correlation matrix showing the
pairwise linkage disequilibrium (LD) be-
tween 10 candidate signals, identified us-
ing an iterative COJO-ASSET analysis
LD was calculated based on the European
ancestry populations in 1000 Genomes
(1000G) Project.conducted a multi-cancer fine-mapping analysis using
PAINTOR for each signal. We first performed fine-mapping
analyses with no functional annotation data imple-
mented. For the ten candidate signals, the size of credible
sets comprising a cumulative 95% PP of causality ranged
from one to fifteen variants (Table 4; Figure S2). All SNPs
identified as lead SNPs in the conditional analysis were
included in the 95% PP credible set of the corresponding
fine-mapping analysis, with six of them having the highest
PP in its set (rs35033501: PP ¼ 0.875; rs35334674: PP ¼
0.987; rs192723047, rs10069690, rs7705526, rs2853677:
PP> 0.999). The fine-mapping analysis based on the signal
identified by SNP rs35226131 included data on colorectal,
glioma, pancreatic, and prostate cancer. Although
rs35226131 was identified as the SNP with the highest PP
of being causal, the PP was relatively modest (PP ¼
0.273) and comparable to nearby SNPs (rs35161420, PP
¼ 0.239; rs61748181, PP ¼ 0.228). Fine-mapping analysis
of the signals indexed by rs11414507 (ER-negative breast
and prostate cancer) and rs465498 (lung, melanoma, and
pancreatic cancer) both identified a SNP located ~5 kb
away from the original lead SNP, with the highest PPs for
rs7712562 (PP ¼ 0.367) and rs380286 (PP ¼ 0.462), respec-
tively. Fine-mapping analysis of rs3888705 (ER-negative
breast, colorectal, ovarian, pancreatic, and prostate cancer)
identified a credible set consisting of 15 variants with PPs
ranging between 0.01 and 0.10, with the lead SNP
rs3888705 having a PP of 0.092.10 Human Genetics and Genomics Advances 2, 100041, July 8, 2021To assess the impact of adding a pri-
ori information on functional impor-
tance, we downloaded tissue-specific
open chromatin narrow peaks of
normal tissues or primary cell lines
for the relevant organs for each signal
from the ENCODE project (Figure 6;
Table S4). By overlapping the func-
tional annotations with the variants
of interest, we repeated the fine-map-
ping analysis for all the candidate sig-
nals (Table 4; Figure S2). Seven of the
ten candidate signals showed consis-
tent 95% PP credible sets as the previ-
ous fine-mapping analyses without
functional annotations. However,
fine-mapping analysis of rs35033501
(ER-negative breast, lung, melanoma,
pancreatic, and prostate cancer) priori-
tized rs71595003, residing in an openchromatin peak for breast epithelial tissue, with a PP of
0.999. In contrast, rs35033501, which had a PP of 0.875
in the analysis without annotations, had a PP < 0.001
when information about open chromatin was added. For
the fine-mapping analyses of rs11414507 (ER-negative
breast, prostate), the size of the 95% PP credible set shrank
from four to two, which included the index SNP
rs11414507 (PP ¼ 0.42) as well as rs7712562 (PP ¼ 0.58).
Both rs11414507 and rs7712562 were located in open
chromatin peaks in breast epithelial tissue. Similarly, after
we implemented the functional annotation data, only two
SNPs were included in the 95% PP credible set of the signal
indexed by rs465498 (lung, melanoma, pancreatic),
compared to eight SNPs in the analysis without functional
information. The index SNP rs465498 had a comparable
PP (0.437) as rs421629 (PP ¼ 0.563), and both SNPs were
located within open chromatin peaks in lung tissue.
Discussion
In this study, we leveraged GWAS summary statistics from
14 cancer types to estimate local genetic correlations and
conduct follow-up fine-mapping of shared cancer regions
in the genome. By partitioning the genome into indepen-
dent blocks as defined by LD, we comprehensively esti-
mated pairwise local genetic correlations between the
included cancers. We identified 13 cancer pairs with signif-
icant local genetic correlation across eight distinct
Table 4. Statistical fine-mapping prioritized the potential causal SNP within 10 independent cross-cancer signals in 5p15.33 region, using PAINTOR v.3.0
Index SNP Fine-mapped cancer types
Fine-mapping without functional prior Fine-mapping with functional priora
95% PP credible setb
PP, index
SNP SNP with highest PP
Highest
PP 95% PP credible set
PP, index





ER-neg BrCa, lung, melanoma,
pancreatic, prostate
rs35033501, rs71595003 0.875 rs35033501
(5:1253918:C:T)





ER-neg BrCa, prostate rs192723047 1.000 rs192723047
(5:1273183:A:G)

































































































0.462 rs421629, rs465498 0.437 rs421629
(5:1320136:G:A)
0.563
aUsed open chromatin narrow peaks identified from the normal tissue or primary cells of the disease-related organs as the functional prior. Open chromatin narrow peaks were obtained from the ENCODE project.













































Figure 6. Open chromatin in different cancer types
Genomic location of tissue-specific open chromatin narrow peaks, which were used as functional prior in the fine-mapping analysis.genomic regions. Among these, one region on chromo-
some 5p15.33 harboring the TERT and CLPTM1L genes
had statistically significant shared heritability for seven
cancer types, including ER-negative breast, colorectal, gli-
oma, lung, melanoma, pancreatic, and prostate cancer.
By utilizing an iterative analysis, we identified ten inde-
pendent cross-cancer SNP signals within this locus. We
then conducted fine-mapping analyses for each indepen-
dent signal and generated 95% posterior probability cred-
ible sets both without and with a priori functional
information.
Our pairwise local genetic correlation results were highly
consistent with the conclusions of previous GWASs and
cross-cancer analyses. The pleiotropic effect of variants in
the 8q24 region between multiple types of cancer,
including colorectal and prostate cancer, has been previ-
ously demonstrated and replicated in studies across popu-
lations of different ancestries.12,59,60 The 5p15.33 region,
containing the TERT and CLPTM1L genes, has also been
associated with multiple cancers.17–23 Other significant
genomic regions identified in our study, including
1q32.1 (ER-negative breast and prostate), 4q24 (colorectal
and prostate), 5q11.2 (overall breast and colorectal),
10q26.13 (ER-positive breast and prostate), 17q12 (endo-
metrial and prostate), and 19p13.11 (ER-negative breast
and ovarian), have also been identified as pleiotropic loci
in previous analyses.61,62 Previous efforts have been
devoted to identifying pleiotropic variants, by using either
a subset-based meta-analysis approach61 or categorizing
genome-wide significant loci of multiple cancers by LD
patterns.62 Our analysis complements these, as we aggre-
gated the per-SNP effect within the loci, estimated the local
heritability of each cancer, and quantified the local genetic
correlation between the cancer pairs. These ‘‘shared herita-
bility hotspots’’ identified in our analysis may contain
genes with strong effect onmultiple cancers or harbormul-
tiple risk variants and biological mechanisms that can
independently affect the risk of different cancers. Our re-
sults can thus be utilized to prioritize candidate regions
for future discoveries of causal variants and functional
follow-up.
As the 5p15.33 region harboring the TERTand CLPTM1L
genes was the only region that displayed more than one
statistically significant pairwise genetic correlation, we
focused our continued efforts on this region. The TERT12 Human Genetics and Genomics Advances 2, 100041, July 8, 2021gene encodes the catalytic subunit of telomerase reverse
transcriptase,25 which is a crucial enzyme for maintaining
telomere length. Mendelian randomization studies have
shown that genetically determined telomere length is asso-
ciated with the risk of multiple cancer types, including gli-
oma, ovarian, lung, and melanoma, but is not associated
with the risk of other cancers included here, such as breast
and prostate.63–65 In our study, we observed local negative
genetic correlations and opposite direction of SNP effects
between specific cancer types, which indicate that genetic
variation in this region is likely to affect cancer risk
through multiple distinct biological pathways, of which
telomere length is only one implicated mechanism. Mean-
while, the CLPTM1L gene encodes the cleft lip and palate-
associated transmembrane-1 like protein, which has been
reported to play a role in cell apoptosis and cytokinesis
and is overexpressed in lung and pancreatic cancer.66–68
Given its important biological function and significant as-
sociation with a broad set of cancers, we assumed that mul-
tiple variants in this region may independently influence
the risk of various types of cancers. By iteratively con-
ducting conditional meta-analyses, we identified ten inde-
pendent signals (seven in the TERT gene, one in the
CLPTM1L gene, and two between TERT and CLPTM1L).
Our study results are comparable to a previous study pub-
lished by Wang et al.,56 which conducted a subset-based
meta-analysis across six types of cancers (bladder, glioma,
lung, pancreatic, prostate, and testicular). Several signals
identified in our study have either been proposed
(rs10069690, rs2853677) or are correlated with the inde-
pendent signals reported in that study (rs7705526 versus
rs7726159, r2 ¼ 0.87; rs465498 versus rs451360, r2 ¼
0.34). We only included cancers with genome-wide signif-
icant signals in this region into the subset-based meta-
analysis and conditional analysis. Compared to the study
presented by Wang et al.,56 our study further included
several common cancers (ER-negative breast, colorectal,
melanoma, and ovarian), while we did not have data on
bladder and testicular cancer. With an increased number
of cancers and larger sample sizes, we were able to refine
the cross-cancer signals in this important region. In addi-
tion, independent signal rs465498 identified in our study
was in strong correlation with two previously identified
susceptible loci at theCLPTM1L gene, including pancreatic
cancer SNP rs31490 (r2 ¼ 0.96)69 and lung, melanoma, and
prostate cancer SNP rs401681 (r2 ¼ 0.96).21,70,71 Our find-
ings imply that the association between the CLPTM1L
gene and various types of cancer can be potentially attrib-
uted to one distinct signal.
When estimating the local genetic correlation across
cancers, we considered subtypes for breast (ER-negative
and ER-positive) and lung cancer (adenocarcinoma, small
cell, and squamous cell). Despite the relatively smaller
GWAS sample size (21,468 for ER-negative breast cancer
compared to 122,977 for overall breast cancer), ER-nega-
tive breast cancer showed stronger associations and higher
genetic correlation with other cancers in the 5p15.33 re-
gion, as compared to ER-positive and overall breast cancer.
In contrast, the three subtypes of lung cancer had either no
genome-wide significant hits at the 5p15.33 region (small
cell) or had weaker local genetic correlation estimates
(adenocarcinoma and squamous cell, data not shown)
than overall lung cancer. We thus included ER-negative
breast cancer and overall lung cancer in the subsequent
analyses.
Multiple lead SNPs with high posterior probability have
been reported to affect telomere length. SNP rs7705526 is
significantly associated with telomere length in multiple
populations.72–75 SNP rs2853677 has been associated
with relative telomere length in a breast cancer case-only
cohort in Han Chinese,76 as well as leukocyte telomere
length in a European ancestry population.75 SNP
rs35226131 is perfectly correlated with a nonsynonymous
variant (rs61748181) in TERT, which results in a protein-
level change from alanine to threonine and negatively in-
fluences telomere length.15,71 SNP rs10069690 has been
found to significantly interact with recent use of non-ste-
roidal anti-inflammatory drugs (NSAIDs) to alter telomere
length in a colorectal cancer case-control study.77 SNP
rs465498, located in the CLPTM1L gene, has been reported
to be significantly associated with telomere length among
Han Chinese.78 We could not find previous data on the
role of other five lead SNPs identified by our study, and it
is thus possible that other unknown mechanisms are
involved.
Since previously identified cancer risk SNPs at 5p15.33
have been linked to open chromatin conformation,55,56
we further included regions of open chromatin for related
tissues from the ENCODE project as functional prior in our
fine-mapping analysis.57 The results for five signals (lead
SNPs rs192723047, rs10069690, rs7705526, rs2853677,
and rs35334674) remained unchanged, with each having
a credible set containing one single SNP with a posterior
probability of 1.00. After incorporating open chromatin
peaks as a prior, the 95% posterior probability credible
sets became smaller for three signals (lead SNPs
rs35033501, rs11414507, and rs465498), as SNPs located
in open chromatin peaks obtained a higher posterior prob-
ability of being causal. For the other two signals (lead SNPs
rs35226131 and rs3888705), the size of each 95% credible
set was relatively large in analyses with and without func-
tional annotations. No SNPs in these regions had a pre-Hudominantly high posterior probability, nor did any of
them overlap with the open chromatin peaks of any
related tissue. The fine-mapping results for these two sig-
nals should thus be interpreted with extra caution.
Our study has several strengths and limitations. We used
cancer GWAS summary statistics published by each collab-
orating consortium, which maximized our sample sizes
and provided large statistical power. This is also the first
study to comprehensively quantify the local genetic corre-
lation across multiple common cancers. We innovatively
adopted the joint analysis pipeline of two-sided ASSET
meta-analysis and COJO-GCTA. This approach enabled
us to both validate the proposed pleiotropic loci and
explore novel independent signals, under the complex ge-
netic architecture in the 5p15.33 region. It is also impor-
tant to recognize some limitations. Although we chose
an internal population (breast cancer controls) to generate
the LD reference panel for the conditional analyses and
fine-mapping, bias may still inevitably exist as the
mismatch of LD between the reference and the population
of other cancers. The study population was limited to Euro-
pean ancestry individuals only, and therefore any conclu-
sions of our research may not be applicable to other ances-
tries. Including multiple ancestries would also allow for
refinement of the fine-mapping signals, since LD structure
varies between populations. Moreover, some of the GWASs
included in the present study (e.g., breast and ovarian)
shared controls. Although we accounted for this overlap
in the local genetic correlation analysis and the subset-
basedmeta-analysis, we were not able to take these into ac-
count in the fine-mapping analysis, as PAINTOR currently
does not adjust for sample overlap. However, we do not
believe this will have a qualitative impact on our results.
Meanwhile, although our analysis included a large number
of cancer types, other cancers, including bladder and
testicular, which have shown genome-wide significant sig-
nals in the 5p15.33 region,21,79 were not included. Further,
we could have missed any potentially causal variants that
were not included in our analyses for various reasons
(e.g., poorly imputed or rare variants). Finally, the tissue-
specific open chromatin peaks used as the functional prior
in our fine-mapping analysis were from adult tissue. Some
of these tissues may not express much of TERT, and thus
these annotations may not necessarily reflect a cellular
context where TERT and the enhancers that promote
TERT expression are active. Our fine-mapping analysis
should thus be interpreted with some caution. Since the
fine-mapping analysis was solely based on bioinformatic
analysis, further functional validation using molecular
biology experiments is required to fully understand the
mechanisms at play in this region.
In summary, our study identified genomic regions with
significant local genetic correlations across 14 types of
common cancers. We further enumerated the independent
pleiotropic signals in the 5p15.33 region and performed a
cross-cancer fine-mapping for each signal, using up-do-
date bioinformatics tools. Results from our study provideman Genetics and Genomics Advances 2, 100041, July 8, 2021 13
novel evidence of the shared inherited basis of human can-
cers and expand our understanding of the role played by
the TERT-CLPTM1L region in cancer development.Declaration of interests
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